Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/BIRC2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/BIRC2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/BIRC2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/BIRC2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/BIRC2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007042312 | Oral cavity | EOLP | nucleotide-binding oligomerization domain containing signaling pathway | 13/2218 | 25/18723 | 1.14e-06 | 2.78e-05 | 13 |
GO:004586125 | Oral cavity | EOLP | negative regulation of proteolysis | 72/2218 | 351/18723 | 1.96e-06 | 4.49e-05 | 72 |
GO:000166624 | Oral cavity | EOLP | response to hypoxia | 65/2218 | 307/18723 | 2.00e-06 | 4.55e-05 | 65 |
GO:003133324 | Oral cavity | EOLP | negative regulation of protein-containing complex assembly | 37/2218 | 141/18723 | 2.01e-06 | 4.57e-05 | 37 |
GO:003587212 | Oral cavity | EOLP | nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway | 13/2218 | 26/18723 | 2.03e-06 | 4.60e-05 | 13 |
GO:000275312 | Oral cavity | EOLP | cytoplasmic pattern recognition receptor signaling pathway | 21/2218 | 60/18723 | 2.55e-06 | 5.64e-05 | 21 |
GO:007048224 | Oral cavity | EOLP | response to oxygen levels | 70/2218 | 347/18723 | 5.00e-06 | 1.02e-04 | 70 |
GO:003629324 | Oral cavity | EOLP | response to decreased oxygen levels | 66/2218 | 322/18723 | 5.31e-06 | 1.07e-04 | 66 |
GO:006145824 | Oral cavity | EOLP | reproductive system development | 81/2218 | 427/18723 | 1.09e-05 | 1.93e-04 | 81 |
GO:004860823 | Oral cavity | EOLP | reproductive structure development | 80/2218 | 424/18723 | 1.51e-05 | 2.50e-04 | 80 |
GO:005160721 | Oral cavity | EOLP | defense response to virus | 55/2218 | 265/18723 | 2.16e-05 | 3.35e-04 | 55 |
GO:014054621 | Oral cavity | EOLP | defense response to symbiont | 55/2218 | 265/18723 | 2.16e-05 | 3.35e-04 | 55 |
GO:000222411 | Oral cavity | EOLP | toll-like receptor signaling pathway | 31/2218 | 121/18723 | 2.21e-05 | 3.37e-04 | 31 |
GO:009730525 | Oral cavity | EOLP | response to alcohol | 53/2218 | 253/18723 | 2.31e-05 | 3.50e-04 | 53 |
GO:006220713 | Oral cavity | EOLP | regulation of pattern recognition receptor signaling pathway | 28/2218 | 105/18723 | 2.46e-05 | 3.65e-04 | 28 |
GO:004312322 | Oral cavity | EOLP | positive regulation of I-kappaB kinase/NF-kappaB signaling | 42/2218 | 186/18723 | 2.54e-05 | 3.75e-04 | 42 |
GO:007042412 | Oral cavity | EOLP | regulation of nucleotide-binding oligomerization domain containing signaling pathway | 8/2218 | 13/18723 | 2.84e-05 | 4.12e-04 | 8 |
GO:001095124 | Oral cavity | EOLP | negative regulation of endopeptidase activity | 52/2218 | 252/18723 | 4.21e-05 | 5.74e-04 | 52 |
GO:190332221 | Oral cavity | EOLP | positive regulation of protein modification by small protein conjugation or removal | 33/2218 | 138/18723 | 5.51e-05 | 7.04e-04 | 33 |
GO:005134625 | Oral cavity | EOLP | negative regulation of hydrolase activity | 70/2218 | 379/18723 | 9.98e-05 | 1.14e-03 | 70 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0412026 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
hsa0513239 | Esophagus | HGIN | Salmonella infection | 69/1383 | 249/8465 | 3.02e-06 | 4.47e-05 | 3.55e-05 | 69 |
hsa0421020 | Esophagus | HGIN | Apoptosis | 36/1383 | 136/8465 | 1.67e-03 | 1.52e-02 | 1.20e-02 | 36 |
hsa046219 | Esophagus | HGIN | NOD-like receptor signaling pathway | 45/1383 | 186/8465 | 3.40e-03 | 2.54e-02 | 2.02e-02 | 45 |
hsa04120111 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
hsa05132115 | Esophagus | HGIN | Salmonella infection | 69/1383 | 249/8465 | 3.02e-06 | 4.47e-05 | 3.55e-05 | 69 |
hsa04210110 | Esophagus | HGIN | Apoptosis | 36/1383 | 136/8465 | 1.67e-03 | 1.52e-02 | 1.20e-02 | 36 |
hsa0462114 | Esophagus | HGIN | NOD-like receptor signaling pathway | 45/1383 | 186/8465 | 3.40e-03 | 2.54e-02 | 2.02e-02 | 45 |
hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa05132211 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
hsa0466810 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
hsa0421027 | Esophagus | ESCC | Apoptosis | 102/4205 | 136/8465 | 1.05e-09 | 1.21e-08 | 6.21e-09 | 102 |
hsa052229 | Esophagus | ESCC | Small cell lung cancer | 69/4205 | 92/8465 | 5.40e-07 | 3.85e-06 | 1.97e-06 | 69 |
hsa015247 | Esophagus | ESCC | Platinum drug resistance | 56/4205 | 73/8465 | 1.85e-06 | 1.13e-05 | 5.78e-06 | 56 |
hsa0514525 | Esophagus | ESCC | Toxoplasmosis | 76/4205 | 112/8465 | 6.83e-05 | 2.90e-04 | 1.48e-04 | 76 |
hsa0451020 | Esophagus | ESCC | Focal adhesion | 127/4205 | 203/8465 | 1.25e-04 | 4.99e-04 | 2.56e-04 | 127 |
hsa0462122 | Esophagus | ESCC | NOD-like receptor signaling pathway | 116/4205 | 186/8465 | 2.90e-04 | 1.03e-03 | 5.30e-04 | 116 |
hsa042156 | Esophagus | ESCC | Apoptosis - multiple species | 25/4205 | 32/8465 | 9.13e-04 | 2.92e-03 | 1.49e-03 | 25 |
hsa040645 | Esophagus | ESCC | NF-kappa B signaling pathway | 67/4205 | 104/8465 | 1.62e-03 | 4.89e-03 | 2.50e-03 | 67 |
hsa052028 | Esophagus | ESCC | Transcriptional misregulation in cancer | 116/4205 | 193/8465 | 2.08e-03 | 5.95e-03 | 3.05e-03 | 116 |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
329 | BIRC2 | TUMOR SUPPRESSOR, KINASE, DRUGGABLE GENOME | | PMID25980951-Compound-1 | | |
329 | BIRC2 | TUMOR SUPPRESSOR, KINASE, DRUGGABLE GENOME | | HGS1029 | | |
329 | BIRC2 | TUMOR SUPPRESSOR, KINASE, DRUGGABLE GENOME | inhibitor | 252827512 | CHEMBL481422 | |
329 | BIRC2 | TUMOR SUPPRESSOR, KINASE, DRUGGABLE GENOME | | PMID25980951-Compound-43 | | |
329 | BIRC2 | TUMOR SUPPRESSOR, KINASE, DRUGGABLE GENOME | | BESTATIN METHYL ESTER | BESTATIN METHYL ESTER | 21515062 |
329 | BIRC2 | TUMOR SUPPRESSOR, KINASE, DRUGGABLE GENOME | | PMID25980951-Compound-4 | | |
329 | BIRC2 | TUMOR SUPPRESSOR, KINASE, DRUGGABLE GENOME | | Birinapant | BIRINAPANT | |
329 | BIRC2 | TUMOR SUPPRESSOR, KINASE, DRUGGABLE GENOME | | PMID25980951-Compound-37 | | |
329 | BIRC2 | TUMOR SUPPRESSOR, KINASE, DRUGGABLE GENOME | antagonist | AT-406 | AT-406 | |
329 | BIRC2 | TUMOR SUPPRESSOR, KINASE, DRUGGABLE GENOME | | PMID25980951-Compound-18 | | |